Suchergebnisse - "Lappegård, Knut Tore"

PubPharm (4)

1

Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study

enthalten in: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis | 2018

von Lappegård, K. | Kjellmo, C. | Ljunggren, S. | +5

2

LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response

enthalten in: Journal of clinical lipidology | 2016

von Lappegård, K. | Enebakk, T. | Thunhaug, H. | +3

3

Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol

enthalten in: Atherosclerosis | 2016

von Lappegård, K. | Enebakk, T. | Thunhaug, H. | +1

4

Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation

enthalten in: The Annals of thoracic surgery | 2004

von Lappegård, K. | Fung, M. | Bergseth, G. | +4

1
[1]